A Study of HS-20089 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
HS-20089 is a novel DAR-6 antibody-drug conjugate （ADC） targeting B7-H4. In preclinical
studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo. The
first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose
limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor
activity of HS-20089 in Patients With Advanced Solid Tumors.